Dimapur News Desk

The Pipeline for Non Alcoholic Fatty Liver Disease will bring a Positive Ray of Hope for a better treatment pattern in the Market in the Upcoming Years

 Breaking News
  • No posts were found

The Pipeline for Non Alcoholic Fatty Liver Disease will bring a Positive Ray of Hope for a better treatment pattern in the Market in the Upcoming Years

June 29
21:55 2021
The Pipeline for Non Alcoholic Fatty Liver Disease will bring a Positive Ray of Hope for a better treatment pattern in the Market in the Upcoming Years

Non Alcoholic Fatty Liver Disease Market
The anticipated launch of pipeline drugs such as Resmetirom (MGL-3196) (Madrigal Pharmaceuticals, Inc.), MSDC-0602K (Cirius Therapeutics), Semaglutide (Novo Nordisk A/S), Ocalive (obeticholic acid or OCA) (Intercept Pharmaceuticals), and others is expected to boost the market during the forecasted period (2021-30).

DelveInsight’s Non Alcoholic Fatty Liver Disease (NAFLD)  market report provides an in-depth understanding of Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology, and Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the Important Findings from the Non Alcoholic Fatty Liver Disease Market Report

  • Non Alcoholic Fatty Liver Disease is the most common chronic liver disease in the United States, according to the American Liver Foundation (n.d.). NAFLD affects around 25% of adults in the United States.

  • According to the study titled “Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study” conducted by Foschi et al. (2018), the prevalence of Non Alcoholic Fatty Liver Disease (NAFLD) was 0.46 (0.41 to 0.51) vs. 0.22 (0.21 to 0.24) in citizens with than in those without altered liver enzymes.

  • Resmetirom (MGL-3196) is a first-in-class, orally administered, small-molecule, thyroid hormone receptor (THR)-selective agonist being developed by Madrigal Pharmaceuticals, Inc.

  • Semaglutide, a long-acting GLP-1 analogue being developed by Novo Nordisk A/S, is a once-daily therapy for Non Alcoholic Fatty Liver Disease.

  • In two current Phase 3 clinical trials, REGENERATE and REVERSE, Intercept’s main drug, Ocalive (obeticholic acid or OCA), is being studied as a potential treatment for advanced fibrosis due to NASH.

  • Various Key companies including Madrigal Pharmaceuticals, Inc., Cirius Therapeutics, Novo Nordisk A/S, Intercept Pharmaceuticals and others are in the process of developing potential therapies for Non Alcoholic Fatty Liver Disease (NAFLD) treatment.

Request sample to know more about NASH @ NAFLD Management Guidelines

The Non Alcoholic Fatty Liver Disease report covers current treatment methods, developing medications, Non Alcoholic Fatty Liver Disease (NAFLD) market share of various therapies, and present and predicted Non Alcoholic Fatty Liver Disease (NAFLD) market size from 2018 to 2030, segmented by seven key markets.

Non Alcoholic Fatty Liver Disease: Overview

Non Alcoholic Fatty Liver Disease (NAFLD) is a very common disorder that refers to a range of disorders in which people who drink little or no alcohol accumulate extra fat in their liver. The most frequent form of NAFLD is fatty liver, which is a non-serious condition.

A small percentage of NAFLD patients may have a more serious condition known as Non-Alcoholic Steatohepatitis (NASH). Fat accumulation in NASH is associated with liver cell inflammation and varying degrees of scarring. NASH is a potentially fatal condition that can result in severe scarring of the liver and cirrhosis.

Non Alcoholic Fatty Liver Disease Epidemiology Segmentation

  • Non Alcoholic Fatty Liver Disease Total Prevalent Cases

  • Non Alcoholic Fatty Liver Disease Type-Specific Prevalent Cases

  • Non Alcoholic Fatty Liver Disease Diagnosed and Treatable Cases

Non Alcoholic Fatty Liver Disease Treatment Landscape

The adoption of lifestyle adjustments focused at increased physical activity and modest, sustained weight loss is currently the mainstay of NAFLD treatment. The FDA has not yet approved any medications to treat NAFLD or NASH. In some cases, insulin-sensitizing drugs are prescribed; however, metformin provided good benefits but only for a short time, thus it is not widely suggested. In some circumstances, pioglitazone is recommended for people who already have Type 2 diabetes.

Non Alcoholic Fatty Liver Disease Market

The predicted launch of pipeline drugs such as Resmetirom (MGL-3196) (Madrigal Pharmaceuticals, Inc.), MSDC-0602K (Cirius Therapeutics), Semaglutide (Novo Nordisk A/S), Ocalive (obeticholic acid or OCA)(Intercept Pharmaceuticals), and others would enhance the market in the forecasted period (2021-30).

Reach out for more insights @ NAFLD Market Size and Share

Non Alcoholic Fatty Liver Disease Pipeline Therapies and Key Companies

  • Resmetirom (MGL-3196): Madrigal Pharmaceuticals, Inc.

  • MSDC-0602K: Cirius Therapeutics

  • Semaglutide: Novo Nordisk A/S

  • Ocalive (obeticholic acid or OCA: Intercept Pharmaceuticals

Table of Contents 

1.

Report Introduction

2.

Non Alcoholic Fatty Liver Disease (NAFLD) Market Overview at a Glance

3.

Disease Background and Overview: Non Alcoholic Fatty Liver Disease (NAFLD)

4.

NAFLD Patient Journey

5.

NAFLD Epidemiology and Patient Population

6.

Non Alcoholic Fatty Liver Disease (NAFLD): Country-Wise Epidemiology

7.

NAFLD Treatment and Medical Practices

8.

NAFLD Unmet Needs

9.

NAFLD Key Emerging Therapies

10.

Non Alcoholic Fatty Liver Disease (NAFLD): Market Size

11.

7MM Non Alcoholic Fatty Liver Disease (NAFLD): Country-Wise Market Analysis

12.

NAFLD Market Drivers

13.

NAFLD Market Barriers

14.

SWOT

15.

Appendix

16.

Report Methodology

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Alcoholic Hepatitis Market

Get comprehensive historical and forecast analysis of Alcoholic Hepatitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as DURECT Corporation, Novartisamong others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories